TRIP12 Antikörper (AA 1-240)

Produktnummer ABIN7151292

Produktdetails anti-TRIP12 Antikörper

Target: TRIP12 (Thyroid Hormone Receptor Interactor 12 (TRIP12))

Bindungsspezifität: AA 1-240

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser TRIP12 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA

Kreuzreaktivität: Human

Aufreinigung: Antigen Affinity Purified

Immunogen: Recombinant Human E3 ubiquitin-protein ligase TRIP12 protein (1-240AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu TRIP12

Target: TRIP12 (Thyroid Hormone Receptor Interactor 12 (TRIP12))

Andere Bezeichnung: TRIP12 (TRIP12 Produkte)

Synonyme: ULF antikoerper, TRIP-12 antikoerper, 1110036I07Rik antikoerper, 6720416K24Rik antikoerper, AA410158 antikoerper, Gtl6 antikoerper, thyroid hormone receptor interactor 12 antikoerper, E3 ubiquitin-protein ligase TRIP12 antikoerper, TRIP12 antikoerper, CpipJ_CPIJ012812 antikoerper, PTRG_06487 antikoerper, LOAG_11488 antikoerper, LOC100631469 antikoerper, Trip12 antikoerper

Hintergrund:

Background: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of \\\'Lys-63\\\'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes.

Aliases: TRIP12 antibody, KIAA0045 antibody, ULF antibody, E3 ubiquitin-protein ligase TRIP12 antibody, EC 2.3.2.26 antibody, E3 ubiquitin-protein ligase for Arf antibody, ULF antibody, HECT-type E3 ubiquitin transferase TRIP12 antibody, Thyroid receptor-interacting protein 12 antibody, TR-interacting protein 12 antibody, TRIP-12 antibody

UniProt: Q14669

Pathways: Nuclear Hormone Receptor Binding